Elranatamab reduced the risk of disease progression or death vs standard care in patients with R/R myeloma after prior anti-CD38 therapy and lenalidomide.
|Videos|September 13, 2019
New Outcomes in Acute Graft-versus-Host Disease
Graft versus Host Disease
Advertisement
Advertisement
Related to this article
The phase 3 VERIFY trial found that rusfertide improved clinical response, reduced phlebotomy requirements, and eased symptom burden in patients with polycythemia vera receiving standard-of-care therapy.
Advertisement
Advertisement
Trending on Targeted Onc
1
ESMO 2026: ADCs and New Combinations Advance Lung Cancer Care
2
340B Contract Pharmacy Case Rekindles Scrutiny Over Program Intent
3
Petosemtamab Plus Pembrolizumab Improves OS in PD-L1+ HNSCC
4
ESMO 2026: New Data Advance Prostate, Kidney, and Bladder Cancer Care
5